Back to Journals » Journal of Asthma and Allergy » Volume 1

Intranasal ciclesonide for allergic rhinitis

Authors Williams, Smith W, Kette G

Published 30 November 2008 Volume 2008:1 Pages 49—54

DOI https://doi.org/10.2147/JAA.S3082

Review by Single-blind

Peer reviewer comments 4


Ben Williams, William B Smith, Frank E Kette

Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, South Australia

Abstract: Ciclesonide is a novel corticosteroid which is optimized for topical use. It is a pro-drug which is activated locally in the airway mucosa, lipid-conjugated for local retention, and has very high protein binding in circulation leading to low systemic bioavailability. These characteristics should lead to highly selective activity with reduced local and systemic side effects. It has been established as an inhaled medication for asthma and has also been shown in double-blind trials to be efficacious for the treatment of seasonal and perennial allergic rhinitis. However no data have yet demonstrated superiority over existing nasal topical corticosteroids, either in terms of efficacy or adverse effects, and trials have not yet clearly shown efficacy in rhinitis in children. Therefore the place of ciclesonide in the treatment of allergic rhinitis relative to other existing products remains unclear.

Keywords: nasal corticosteroid efficacy, ciclesonide, allergic rhinitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]